Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Harvard Business School
McKinsey
Mallinckrodt
AstraZeneca

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ASP015K

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug ASP015K?

ASP015K is an investigational drug.

There have been 32 clinical trials for ASP015K. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2012.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Psoriasis. The leading clinical trial sponsors are Astellas Pharma Inc, Astellas Pharma Global Development, Inc., and Janssen Biotech, Inc.

There are eight US patents protecting this investigational drug and seventy-eight international patents.

Recent Clinical Trials for ASP015K
TitleSponsorPhase
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsAstellas Pharma China, Inc.Phase 1
A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)Astellas Pharma China, Inc.Phase 3
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminAstellas Pharma IncPhase 1

See all ASP015K clinical trials

Clinical Trial Summary for ASP015K

Top disease conditions for ASP015K
Top clinical trial sponsors for ASP015K

See all ASP015K clinical trials

US Patents for ASP015K

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP015K   Start Trial Kinase inhibitors Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB)   Start Trial
ASP015K   Start Trial Kinase inhibitors Respivert Limited (N/A) Topivert Pharma Limited (London, GB)   Start Trial
ASP015K   Start Trial Heterocyclic janus kinase 3 inhibitors Astellas Pharma Inc. (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Colorcon
Express Scripts
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.